Close Menu

NEW YORK – Singaporean firms Inex Innovations and Exchange and Nova Satra Dx this week announced their merger and decision to focus on offering diagnostic testing and precision healthcare to Asian women.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women. The deal is valued at $72 million and is backed by investors including Kuala Lumpur, Malaysia-based Genting, as well as Enterprise Singapore and SNS Holdings, both based in Singapore.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.